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Defining Benchmarks for Major Liver Surgery
A multicenter Analysis of 5202 Living Liver Donors
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Objective: To measure and define the best achievable outcome after major
hepatectomy.
Background: No reference values are available on outcomes after major
hepatectomies. Analysis in living liver donors, with safety as the highest
priority, offers the opportunity to define outcome benchmarks as the best
possible results.
Methods: Outcome analyses of 5202 hemi-hepatectomies from living donors
(LDs) from 12 high-volume centers worldwide were performed for a 10-year
period. Endpoints, calculated at discharge, 3 and 6 months postoperatively,
included postoperative morbidity measured by the Clavien-Dindo classifi-
cation, the Comprehensive Complication Index (CCI), and liver failure
according to different definitions. Benchmark values were defined as the
75th percentile of median morbidity values to represent the best achievable
results at 3 month postoperatively.
Results: Patients were young (34  [9] years), predominantly male (65%)
and healthy. Surgery lasted 7  [2] hours; 2% needed blood transfusions.
Mean hospital stay was 11.7 [5] days. 12% of patients developed at least 1
complication, of which 3.8% were major events (grade III, including 1
death), mostly related to biliary/bleeding events, and were twice higher after
right hepatectomy. The incidence of postoperative liver failure was low.
Within 3-month follow-up, benchmark values for overall complication were
31 %, for minor/major complications 23% and 9%, respectively, and a
CCI 33 in LDs with complications. Centers having performed 100
hepatectomies had significantly lower rates for overall (10.2% vs 35.9%,
P < 0.001) and major (3% vs 12.1%, P < 0.001) complications and overall
CCI (2.1 vs 8.5, P < 0.001).
Conclusions: The thorough outcome analysis of healthy LDs may serve as a
reference for evaluating surgical performance in patients undergoing major
liver resection across centers and different patient populations. Further
benchmark studies are needed to develop risk-adjusted comparisons of
surgical outcomes.
Keywords: Comprehensive Complication Index, left hemi-hepatectomy,
living donor, right hemi-hepatectomy
(Ann Surg 2016;264:492–500)
I ncreasing demands for quality assessment in surgery has led to thesearch for new methodologies to convincingly evaluate complex
and expensive procedures. Comparison of results between centers,
different periods of times or alternative therapies are currently
unreliable. One central drawback is the lack of standard outcome
measures or metrics, against which the results of a procedure may be
convincingly compared. For example, although centers may report
on large series of liver resections and claim superior outcome, the
‘‘optimal’’ or best achievable postoperative results remain speculative.
This leads to the concept of benchmarking, which is a process
of measuring performance across health care providers, with the aim
of improving performance and reduce unwarranted variation in
health care delivery.1 Often benchmarking is used to compare 1
endpoint–for example, 1-year survival–of a procedure for a specific
center versus the average or median data of other centers in a region
or a country.2 Although informative–with a main aim to rouse
competition and a search for improvement in individual centers–
such an approach fails to present a wider spectrum of relevant
endpoints as well as comparison with the best achievable results.
With this in mind, we embarked in a novel approach identify-
ing relevant benchmark endpoints for complex and well-defined
procedures. We propose living donor (LD) hepatectomy as a unique
model for benchmarking in liver surgery. We initiated this work for
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anatomic right hepatectomy (RH) and left hepatectomy (LH). Our
hypothesis (starting point) was that the ‘‘best’’ achievable results
come from LD operations as only standardized types of hepatec-
tomies are performed, with safety as the highest priority. Such
operations are conducted with maximum attention to all details
and exclusively in healthy, low-risk individuals. Second, we selected
only centers with high experience, having performed at least 50 cases
of adult LD, and included centers covering 4 continents. Third, we
identified a number of clinically relevant and reproducible endpoints.
With these requirements, we postulated that the results of this
complex procedure performed in such large population under the
best available settings may serve to establish the optimal–better
labeled ‘‘best achievable’’– benchmark for major hepatectomies
(Figs. 1 and 2).
METHODS
Study Design
Data were obtained in 12 high-volume liver centers covering the
4 continents for a 10-year period (January 1, 2004–December 31,
2014) with an experience of at least 50 LD operations. Each center had
a prospectively collected database, from which most of the data was
extracted. Charts were thoroughly reevaluated in each patient, who had
a complicated postoperative course or unclear information. Only
patients who underwent an anatomical RH or LH were analyzed. Pure
laparoscopic procedures were excluded. The centers included the
Hospital Clinic de Barcelona, Spain; Hospital Italiano de Buenos
Aires, Argentina; University Hospitals Saint Luc Brussels, Belgium;
University Hospital Ghent, Belgium; Lahey Hospital and Medical
Center Burlington, USA; Kaohsiung Chang Gung Memorial Hospital,
Kaohsiung, Taiwan; Paul Brousse Hospital, Paris, France; University
of Pennsylvania, USA; University of Tokyo, Japan; Toronto General
Hospital, Canada; University of Ulsan Seoul, Korea; and the University
Hospital of Zurich, Switzerland.
The aim of the study was to define specific benchmark values
for well-defined endpoints describing postoperative morbidity after a
major hepatectomy. If centers had higher postoperative morbidity
than defined by the benchmark values, it would indicate a need to
enquire about potential causes and quality improvement processes. If
centers had lower postoperative morbidity than defined by the
benchmark values, it would mean that postoperative morbidity
is acceptable.
In agreement with each participating center, center-specific
data are reported anonymously in this study, that is, without dis-
closure of the identity of the respective centers. Appropriate ethical
approval from the institutional ethical board of the University
Hospital of Zurich and from each respective center was obtained
before analysis of the data.
Performance Metrics of Benchmarking
Five parameters of postoperative morbidity including com-
plications of any severity, minor and major complications, the
Comprehensive Complication Index (CCI), and postoperative liver
failure served as performance metrics to define benchmarks for open
RH and LH. All postoperative morbidity data were collected for the
postoperative period of hospitalization and for the 3- and 6-month
period after surgery.
Each postoperative complication occurring during the initial
stay or after readmission was graded according to the severity-
oriented Clavien-Dindo complication system.3,4 Minor and major
complications were defined as grade II and grade III, respect-
ively. Furthermore, the cumulative postoperative morbidity was
assessed using the novel metric for postoperative complications–
the CCI5,6, which measures the overall morbidity on a scale from 0
(uneventful) to 100 (death).
LD characteristics including age, sex, comorbidities, preop-
erative laboratory tests, and volumetry of the right and left hemi-
liver, as well as available percentage of (macro and micro) steatosis
obtained on biopsies were collected. Characteristics of surgery
included following variables: duration of operation, transection
technique and device, need for Pringle maneuver, intraoperative
blood loss, and transfusion, as well as any ‘‘atypical’’ intraoperative
events. Particular attention was given to the preservation of the
middle hepatic vein for the donor or recipient. Postoperative labora-
tory values were collected for aspartate aminotransferase, alanine
aminotransferase, bilirubin, alkaline phosphatase, gamma glutamyl
transferase, creatinine, international normalized ratio (INR), hem-
atocrit, hemoglobin, and platelet count.
FIGURE 1. Shows the overall and major (III) complication
rate in % in the respective centers within 3 months follow
up. Black indicates overall complication rate; Grey¼major
complication rate.
FIGURE 2. (A) and (B) show mean ala-
nine aminotransferase and aspartate ami-
notransferase levels after right (RH) and
left hemihepatectomy (LH) from preop-
erative to postoperative day 7.
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Post-hepatectomy liver failure (PHLF) was assessed by 4
commonly reported criteria including International Study Group for
Liver Surgery (ISGLS),7 50–50 criteria,8 and bilirubin>7,9 as well as
our criteria for small-for-size syndrome (SFSS) described in 2005,10
which are defined as following: ISGLS criteria are INR and bilirubin
above the normal cutoff, as defined by local laboratory on day 5 after
liver resection. Because our data relate to many different local labora-
tory standards, we set an INR 1.3 and bilirubin 1.2 mg/dL as
thresholds,7 and the presence of biliary complications were not
considered as an exclusion criteria. The 50–50 criteria are defined
as INR1.7 (Quick 50%) and serum bilirubin2.9 mg/dL (50mmol/
L) on postoperative day 5, predicting in the original report a mortality
of 50%.8 The bilirubin 7 criteria relies on serum bilirubin levels>7 mg/
dL (119mmol/L) on postoperative day 5 in noncirrhotic and non-
cholestatic patients.9 Our definition of SFSS relies on 3 factors:
bilirubin >5.9 mg/dL (100mmol/L), INR >2 and the presence of
encephalopathy grade 3 or 4. At least 2 of those factors must be
present on 3 consecutive days within the first week after surgery.10
Statistical Analysis
Benchmark values were determined for the 5 parameters of
postoperative morbidity, that is, complications of any severity, minor
and major complications, the CCI and liver failure, all of them until
hospital discharge and up to 3 and 6 months after surgery. For each
center, we first calculated the proportion of LD with at least 1
complication of any severity, minor and major severity, liver failure
as well as the median CCI of patients with at least 1 grade II
complication. We then calculated the median proportions and the
median of the median CCIs across centers and defined the benchmark
range by the 25th and 75th percentile. Thus, morbidity values (eg,
proportion of patients with a major complication) below the bench-
mark value (75th percentile) indicate acceptable morbidity, values
above the benchmark value indicate high morbidity, whereas below
the benchmark value (25th percentile) indicate very low morbidity.
We also conducted descriptive statistics for various intra- and
postoperative parameters in order to characterize the collective of
LDs because it is the most comprehensive described so far.
RESULTS
From the 12 centers included in the study, we collected a series
of 5202 LD cases, of which 4206 (81%) were anatomical RH and
996 (19%) anatomical LH. The numbers per center varied widely
between 36 and 3257. Three centers performed more than 400
procedures, whereas 7 performed less than 100.
LD characteristics are summarized in Table 1. Of note, this
population was at low surgical risk, with a very low rate of car-
diopulmonary comorbidities (<1%) reflecting an American Society
of Anesthesiology (ASA) score II in 99.9% of patients. Mean LD
age was 31 (standard deviation [SD] 10) years, with 61% males. The
mean body mass index (BMI) was 23.5 kg/m2 [3.5] reflecting a
stringent selection policy. Preoperative laboratory values were within
normal range in all patients, showing for example a mean bilirubin
level of 0.8 mg/dL [0.4] (13.6mmol/L [6.8]) and mean INR of 1.0.
Mean hematocrit and creatinine levels were 42% [4.2] and 0.8 mg/dL
[0.17] (70.4mmol/L [15]), respectively.
Characteristics of Hepatectomy
The characteristics of surgical procedures are summarized in
Table 2. Procedures were performed through laparotomy and ful-
filled the criteria for anatomic RH or LH. Mean duration of surgery
was 7.7 [2] hours (7.5 [2] in RH vs 8.3 [3] in LH). The modified
Makuuchi incision, also labeled as reverse L-incision–that is, with-
out thoracotomy–was the most frequently used access (71% in RH vs
TABLE 1. Patient Characteristics
All (n ¼ 5202) RH (n ¼ 4206) LH (n ¼ 996)
Age, yrs [SD] 30.9 [9.8] 30.0 [9.7] 34.1 [9.7]
Sex (male/female) 3189 (61.3%) / 2013 (38.7%) 2535 (60.3%) / 1671 (39.7%) 654 (65.7%) / 342 (34.3%)
ASA score
 II 5195 (99.9%) 4200 (99.9%) 995 (99.9%)
 III 7 (0.1%) 6 (0.1%) 1 (0.1%)
BMI, kg/cm2 [SD] 23.5 [3.5] 23.4 [3.5] 24.4 [3.3]
TABLE 2. Surgery-related Characteristics
All (n ¼ 5202) RH (n ¼ 4206) LH (n ¼ 996)
Type of incision
Modified Makuuchiy 3734 [71.8%] 2983 [70.9%] 751 [75.4%]
Subcostal 810 [15.6%] 787 [18.7%] 23 [2.3%]
Midline 55 [1.1%] 22 [0.5%] 33 [3.3%]
Mercedes 45 [0.9%] 40 [1.0%] 5 [0.5%]
Pringle maneuver (%) 147 [2.8%] 100 [2.4%] 47 [4.7%]
Mid hepatic vein taken with the graft (%) 1169 [22.5%] 239 [5.7%] 930 [93.4%]
Transsection devicez
Cusa 4483 [86.2%] 3513 [83.5%] 970 [97.4%]
Hydrojet 586 [11.3%] 568 [13.5%] 18 [1.8%]
Kelly-crush clamp 5 [0.1%] 4 [0.1%] 1 [0.1%]
Surgery time, min 461 [122] 451 [102] 501 [176]
Intraoperative transfusions (%) 109 [2.1%] 100 [2.4%] 9 [0.9%]
Unclear information or combined in 10.6%.
yAlso labeled as reverse-L incision; does not include thoracotomy.
zUnclear information in 2.4%.
Values in square brackets are SDs.
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75% in LH), almost exclusively used in Asia (99%), followed by the
subcostal incision (19% in RH vs 4.4% in LH), the preferred incision
in Europe and North America (71%). Cavitron Ultrasonic Surgical
Aspirator was the most commonly used transection device (83% in
RH vs 97% in LH), followed by hydrojet (11%, n ¼ 586). One
hundred nine LD (2.1%) received intraoperative blood transfusions
with lower rate of transfusion in LH (0.9%) versus 2.4% in RH.
Pringle maneuver was used in 2.4% of RH and 4.7% of LH mostly for
single short periods. Mid hepatic vein was taken in 5.7% of RH and
93.4% of LH. No hepatic vein reconstructions have been performed
in donors.
Morbidity After RH and LH
Mean length of hospital stay was 11.7 [5.3] days (11.7 [5.6] in
RH vs 11.8 [4.1] in LH). Transfusion after surgery was a rare event
with only 28 patients (0.5%) requiring blood (0.6% in RH vs 0.1% in
LH), and only 2 receiving more than 2 erythrocyte concentrates.
Outcome after RH and LH is summarized in supplementary Table 6,
http://links.lww.com/SLA/B46. Minor complications (grade II)
were comparable after RH and LH, but major complications (grade
grade III) were significantly higher after RH. Incidence rate of major
complications after RH at discharge, 3 and 6 months, was 3%, 4%,
4.1%, respectively, versus 1.4% (P ¼ 0.001), 2.0% (P ¼ 0.008), and
2.2% (P ¼ 0.014) after LH.
Seventy five patients (1.5%) developed a complication IIIb,
most occurred during hospitalization (n ¼ 59, 1.1%), whereas 18
occurred between discharge and the third postoperative month, and
another 7 between 3 and 6 months. The incidence rate for compli-
cations IIIb after RH and LH at discharge, 3 and 6 months was
1.3%, 1.4%, 1.5% versus 0.6%, 0.8%, 1.0%, respectively (P ¼ 0.03,
P ¼ 0.14, P ¼ 0.3).
Complications grade IV (n ¼ 7, 0.13%) were only observed
after RH, which included cardiopulmonary complications (n ¼ 4),
inferior vena cava thrombosis (n ¼ 2), and 1 death (grade V) related
to intraoperative cardiac arrest. No other fatal outcome occurred in
the follow-up showing an overall mortality of 0.02% in the 3 or
6 months follow-up.
The mean CCI after RH and in patients who developed
a complication at discharge, 3 and 6 months was 20.6, 21.6
and 21.8, respectively. In contrast after LH, those figures were
18.5 (P ¼ 0.17, when compared to RH), 19.1 (P ¼ 0.05) and 19.4
(P ¼ 0.08).
Incidence and Severity of Complications
During the follow-up, 628 LD (12%) developed 817 post-
operative complications; 13% (n ¼ 536) after RH versus 9.2% (n ¼
92) after LH (P< 0.01). Although 488 LD (417 (9.9%) after RH and
71 (7.1%) after LH developed complications during the initial
hospitalization, 140 patients developed their complications after
initial discharge, mostly due to cardiopulmonary and biliary events,
as well as wound infections. Between 3 and 6 months after surgery,
only 6 operative revisions were required, for incisional hernias (n ¼
4), re-laparotomy for adhesive small bowel obstruction (n ¼ 1) or for
bile duct stenosis (n ¼ 1).
As shown in supplementary Table 7, http://links.lww.com/
SLA/B46, the most common types of complications were of biliary
(n ¼ 146, 18% of total complications) and cardiopulmonary (n ¼
115, 14%) origins. Considering the total number of 248 major
complications, biliary (n ¼ 79, 32%) and cardiopulmonary (n ¼
47, 19%) events as well as abdominal bleeding (n ¼ 31, 12.5%) and
intra-abdominal collections (n ¼ 31, 12.5%) represented more than
two-thirds of all major complications. Minor complications were
predominantly related to biliary problems (n ¼ 65, 11.5%) or wound
infections (n ¼ 86, 15%).
Looking at biliary complications, 87% (n ¼ 127) occurred
after RH vs 13% (n ¼ 19) after LH. 44.5% (n ¼ 65) of biliary
complications were minor and did not require operative manage-
ment. Biliary drainage or stenting (grade IIIa) was performed in 29
patients after RH, whereas 16 patients required re-operations (grade
IIIb). Four LD developed biliary strictures, which were treated
conservatively (n ¼ 1), by biliary stenting (n ¼ 1) and reoperations
after 2 and 14 weeks after LH (n ¼ 2). From discharge to 6 months
follow-up, 37 patients developed 43 biliary complications, only 2 of
them after LH. Most of them were grade IIIa due to biliary leakage or
bilioma. Two LD’s required reoperation due to biliary strictures
after discharge.
Regarding the 115 patients (2.2%), who developed cardio-
pulmonary complications, the vast majority occurred after RH (n ¼
110; 96%), whereas only in 4% (n ¼ 5) after LH. Most of them
required thoracocentesis (grade IIIa), mostly (>90%) after RH.
Looking at the 75 patients (1.4%), who developed more severe
events (grade IIIb), 27 were re-laparotomies due to postoperative
bleeding; 17 due to biliary leakage, bile duct injuries or strictures.
One patient required re-laparotomy due to ruptured biliary drain and
2 donors required T-tube placement for injuries of the common
bile duct.
Influence of Center Volume on Donor Outcome
Significant association was observed between center volume
and number of complications. Centers having performed 100
hepatectomies had significantly lower rates for overall (10.2% vs
35.9%, P < 0.001) and major complications (3% vs 12.1%, P <
0.001). Furthermore overall CCI and CCI in patients with compli-
cations was significantly lower in high-volume centers (2.1 vs 8.5
and 20.7 vs 23.6 with P < 0.001 and P < 0.003, respectively).
Post-hepatectomy Liver Failure
Reflecting the overall healthy population and low compli-
cation rate, PHLF was a rare event and occurred almost exclusively
after RH with discrepancies in incidence according to the 4 defi-
nitions evaluated, ISGLS, 50/50, bilirubin 7 and our criteria for SFSS
(Table 3). No patient experienced PHLF according to the ‘‘50–50’’
criteria. Ten patients with RH (0.2%) met the day 5 bilirubin >7
criteria, only 1 of them had associated complications according to the
Clavien-Dindo grading system in the form of a paracentesis (grade
IIIa) for ascites. Two patients recovered spontaneously from the
jaundice within 2 weeks and 2 patients underwent an endoscopic
retrograde cholangiography, which failed to show any abnormalities.
One patient met our criteria for SFSS (0.02%), with bilirubin levels
and INR above the limit on 3 consecutive days and required para-
centesis (grade IIIa) for ascites.
According to the ISGLS criteria, 259 LD (5%) developed
PHLF with the vast majority after RH (99%, n ¼ 256) vs only 1% (n
¼ 3) after LH; P < 0.01). Three-quarters of these cases (n ¼ 204,
79%) did not require changes in post-operative management, that is,
not captured by the complication grading system, whereas 55
patients (21%) developed complications within 3 months, most of
them cardio-pulmonary or urinary tract complications, not obviously
related to liver failure. Thus, these 259 patients fulfilling the ISGLS
criteria developed 21 (27.5%) grade I, 28 (37%) grade II, 19 (25%)
grade IIIa, and 8 grade IIIb (10.5%) complications.
Benchmark value for patients positive according to the ISGLS
criteria is 4.8% and 3.4% for those associated with at least 1
complication according to Clavien-Dindo grading system.
Postoperative Laboratory Profile
Laboratory values are summarized in Table 3. Patients after
RH showed significant higher aspartate aminotransferase and
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bilirubin levels (P < 0.001), as well as lower mean platelets nadir (P
< 0.001). Mean lowest INR was 1.5 in both groups. Mean creatinine
levels peaked within 48 hours after surgery and values were com-
parable between RH and LH groups. Creatinine levels normalized in
>99% of patients within 1 week of surgery.
Hospital Readmission
Readmission rate within 30 days was 2.8% (n ¼ 134), with
2.6% after RH (n ¼ 111) and 2.3% after LH (n ¼ 23) (P ¼ 0.09).
Main causes for readmission within 30 days were biliary or cardi-
opulmonary problems. The most common presentation at readmis-
sion was fever and abdominal pain. Of all readmitted patients, 11
(8.2%) required reoperation at readmission. Three patients under-
went incisional hernia repair and 3 cases of adhesiolysis due to bowel
obstruction. Two patients were re-operated for biliary leakage with
peritonitis and 2 for biliary strictures at 2 and 14 weeks after
operation. One patient required major intervention due to deep
vein thrombosis.
Benchmark Values
Benchmark values target postoperative morbidity including
complications by grade of severity, minor (II) and major (IIIa)
complications, as well as the CCI in patients having developed
at least 1 complication (Table 4). The upper value for overall
complication rate is 31%, minor complications 23%, and major
complications 8.1%. At the time of discharge, these values were,
respectively, 27%, 19%, and 6%, with then only negligible changes
between 3 and 6 months. Benchmarks for CCI in patients with
complications at discharge, 3 and 6 months, were 27.9, 32.6, and
32.7, respectively.
DISCUSSION
Based on this multicentric study, we propose a new concept for
benchmarking the best available outcome for complex surgical
procedures serving as reference values for comparisons. To bench-
mark major liver resection, we chose anatomic right and left hemi-
hepatectomies, performed under the optimal conditions of living
donation.11–16 The main findings were a low morbidity rate with
only 12% of patients developing a complication, a low CCI indi-
cating most minor events, with more serious complications after RH
compared with LH.
To secure credible data collection, we enrolled a large number
of patients and selected centers for excellence from all around the
world. Although the criteria for ‘‘excellence’’ remain vague and
subjective, we agreed on having high volume liver centers that have
experience with at least 50 LD operations and hold prospective
databases, from which all relevant information could be gathered.
Another condition was previous publications critically reporting on
the outcome of liver surgery.
Many stakeholders in medicine, including patients, are
requesting data on quality. This has resulted in mandatory reporting
in national database, audits, and a rise in self-reporting in the lay and
medical literature. In a number of countries, data are made publically
available, and the respective centers–or sometimes surgeons–are
compared with the average or median values covering the whole
country. Usually a single parameter ‘‘1-year mortality’’ or ‘‘peri-
operative mortality’’ is reported. Although such policy enables
comparisons of individual centers with the country benchmark,
the obvious drawbacks are at least threefold: first the lack of credible
comparison with larger number of patients and extranational centers,
second the reporting of only 1 single endpoint (such as mortality),
and third, the absence of risk adjustment.
The novel concept of benchmarking is different, as it allows
comparison with the ‘‘best possible’’ results for the respective
procedures targeting several clinically relevant endpoints. We also
incorporated the CCI, the novel metric for morbidity, integrating all
complications on a scale from 0 (no complication) to 100
(death).5,6,17 The concept for such benchmarking for the ‘‘best
TABLE 4. Benchmark Values
At Discharge
After 3
Months
After 6
Months
Any complication 26.9% 31.2% 31.2%
Major complications (IIIa) 6.0% 8.1% 9.2%
Minor complications (II) 18.9% 22.6% 22.6%
CCI 27.9 32.6 32.7
Liver failure
ISGLS 4.8% Same —
With complications 3.4% Same —
Values are the 75th percentile of median proportions. ISGLS, defined as positive
according to the International Study Group for Liver Surgery, as INR 1.3 and bilirubin
1.2 mg/dL on postoperative day 5.
TABLE 3. Postoperative Laboratory Results and PHLF
RH LH P
Peak aspartate aminotransferase (reference <35 U/L) 207 [149] 204 [156] <0.001
Peak alanine aminotransferase (reference <35 U/L) 222 [726] 234 [187] 0.37
Peak bilirubin (reference <21mmol/L/<1.2 mg/dL) 49.3 [28.9] / 2.9 [1.7] 30.6 [17] / 1.8 [1] <0.001
Peak creatinine within 48 hours after surgery (reference <80 mmol/L/0.9 mg/dL) 63.7 [19.5] / 0.72 [0.22] 63.7 [15] /0.72 [0.17] 0.026
Creatinine after 1 week (reference <80 mmol/L/0.9 mg/dL) 64.5 [18.5] / 0.73 [0.21] 67.2 [16] / 0.76 [0.18] 0.020
Peak INR 1.5 [1.1] 1.5 [5.7] 0.88
Nadir platelets (G/L) 154 [39] 170 [38] <0.001
4 definitions of liver failure:
ISGLS criteria, n (%) 256 (6) 3 (0.3) <0.01
50–50 criteria, n (%) 0 0
Bilirubin day 5 >7 criteria, n (%) 10 (0.24) 0
SFSS, n (%) 1 (0.02) 0
All results reported as mean with SD in square brackets.
ISGLS criteria for PHLF: When INR and Bilirubin are above the normal cut-off as defined by local laboratory on day 5 after liver resection. Due to many different laboratory
standards, we set INR 1.3 and bilirubin 1.2 mg/dL.
50–50–criteria are considered positive with INR 1.7 and serum bilirubin 2.9 mg/dL on postoperative day 5. Bilirubin >7 mg/dL on the 5th postoperative day: positive, when
bilirubin >7 mg/dL in noncirrhotic, noncholestatic patients.
Criteria for SFSS: positive, with 2 of the following criteria on 3 consecutive days: bilirubin >5.9 mg/dL, INR >2, encephalopathy grade 3 or 4.
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outcome’’ is easy to understand and apply, and therefore likely to get
wide acceptance.
The CCI is an important new tool to better assess the actual
burden of complications on the whole postoperative course. Record-
ing complications individually and reporting only the most severe
one, as usually done in most studies6 fails to provide information
about the cumulative (overall) morbidity. The CCI informed on all
complications balancing their weight by severity. This sensitive and
clinically relevant endpoint seems key for future benchmark projects,
also enabling longitudinal assessment of the cumulative morbidity,
for example, at discharge versus 3 or 6 months. For example, in this
study, the CCI was the most sensitive marker highlighting better
outcome in larger programs. CCI will even gain increasing value in
analyzing procedures with higher rates of complications.6
Importantly, benchmarking analyses should present ranges,
above which comparative results are significantly poorer, or signifi-
cantly better if they are below. In the current study, involving a
patient population associated with low morbidity, only the upper
threshold of the range is of value to serve as the marker for acceptable
versus higher complication rates in analyzing other populations. It is
crucial for benchmarking analysis to select the relevant endpoints for
the specific procedures which best measure the performance of a
procedure. For example, benchmark endpoints for liver surgery must
not only include complications and CCI but also postoperative liver
failure and readmission rates. In Table 5, looking for some standard-
ization, we propose the minimum endpoints to include in future
benchmarking studies. The duration of the follow-up has also been
controversial.18 It is obvious that limiting the observation to the
hospital stay is insufficient due to major center variations, and a
consensus seems to arise proposing a minimum of 3 months.19–27 In
the current study, a number of events occurred between the time of
discharge and 3 months postoperatively, but very few afterward
corroborating the standardized use of benchmarking at 3 months.
Morbidity rate was consistent with many studies,14,28–32 but
some showed values above the benchmark.33,34 For example, our
morbidity rate was lower than the 38% published by the adult-to-
adult living donor liver transplantation (A2ALL) group.34 One
possible explanation for this observation might be related to the
larger number of LD (5202 vs 392). Another reason could be the
lower proportion of obese donors with a lower average BMI com-
pared with the 60% of overweight donors in the A2ALL group.34 In
addition, there was a lack of clearly defined standard outcome
measures, as complications were only assessed as ‘‘peri- and post-
operative’’ events, not focusing on 3 and 6 months morbidity, as now
widely proposed.19–27 Moreover, A2ALL study group used an earlier
version of complication grading, and not the most recent and widely
accepted version of the Clavien-Dindo classification.3
Of course, interpretation of any outcome data must be risk-
adjusted accounting for cases that mix across different populations
(eg, different centers) and time (eg, within a center). Approaches for
risk adjustment need to be developed, which include appropriate
patient characteristics as well as statistical models as it has been done
for other fields.35–37 In liver surgery we expect poorer results than the
benchmark values. For example, major hepatectomies for cancer,
after chemotherapy, or in the presence of underlying liver diseases
will be associated with higher complication rates and thereby higher
CCI. In fact, the best results of specific diseases, for example,
separating malignant from benign diseases or in cirrhotic patients,
should be made available through another benchmarking study.
Compared with other organs, benchmark values like those obtained
in LD are not available because no surgery is performed in patients
without diseases. Benchmarking will have to be deducted from
selected high-quality programs for selective procedures.
Several additional questions can be addressed with bench-
marking data. There are accumulating studies suggesting a corre-
lation between program volume and outcome.38,39 Although the
current study was not designed to look at the impact of center
volume on outcome, we observed a significant influence of the
number of cases per center and outcomes for this highly standardized
procedure and low-risk population. For example, arbitrarily selecting
a cutoff of 100 cases, we found significant decrease in overall and
major complications as well as CCI in larger programs. Highlighting
that center effect goes well beyond the selection of patients. The
analyses also revealed that the rate of major complications was about
twice higher in RH, when compared with LH, whereas no other
differences could be detected. This has important implication in
living donation favoring left donation as far as this would have
negative impact on the recipient.12,28,34,40–43
In liver surgery, an important endpoint–often imbedded in the
reporting of complications–is postoperative liver failure, also labeled
‘‘small-for-size’’ syndrome,10,44,45 although no consensus exists on
this definition. We tested 4 commonly used definitions,7–10 and
found that only 1, ISGLS,7 captured some postoperative liver dys-
function in this series. The incidence was, however, low (<5%),46,47
and about two-thirds of them had no clinical relevance due to an
uneventful course without any associated complication; correspond-
ing to the subgroup of ISGLS A of the 3 categories (A, B and C)
described in the original article.7 Looking at the other third of liver
failure, almost half of the developed complications were unrelated to
the liver failure, such as urinary tract infections. Thus, only 1% of the
total population developed liver dysfunction associated with clin-
ically relevant complications.48 We suggest, however, that postop-
erative liver failure remains included in the reporting of major
hepatectomy in future studies.49 The weight on the morbidity
associated with liver failure should, however, be included into the
standardized description of complications, as well as CCI, to secure
consistency in reporting clinically relevant information.
In this report, we also evaluated additional parameters, which
might not be of major clinical relevance such as postoperative
laboratory tests. For example, the observation that serum transam-
inases are higher after LH than RH is of little interest and the use for
comparisons with future studies is questionable. We would suggest
making such reporting facultative.
This study has some inherent limitations particularly regard-
ing missing data collections. Despite the availability of a prospective
database in each center and the retrospective analysis of each case
with unclear information, one cannot exclude that some events were
not captured.50 The low rate of minor complications in one of the
largest centers triggered a careful reevaluation of the charts, but this
did not lead to significant changes in the data. Another limitation
may be that the severity of complications may have been misclassi-
fied in some instances because information on the therapeutic con-
sequences of complications were not always fully available.
TABLE 5. Proposal for Standardized Reporting for Bench-
marking
1. Include large volume centers from at least 3 continents
2. Availability of a prospective database in each center
3. Standardized complication grading system by severity
4. Standardized metric for morbidity (eg, CCI)
5. Types of complications by severity
6. Assessment of postoperative organ failure (when appropriate)
7. Three months follow-up after surgery
8. Readmission rate
9. Benchmark ranges with lower and upper limits
10. Long-term oncologic results, when appropriate
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In conclusion, we consider this project as an inaugural study
introducing a novel concept of benchmarking in surgery. The avail-
ability of ‘‘best achievable’’ results should serve to conclusively
benchmark the results in individual centers, over time or even with
alternative nonsurgical approaches. In every analysis comparing
outcomes across centers and time, risk adjustment must be used
to account for different case mix and allow for proper interpretation.
Future work in liver surgery should target major hepatectomies for
benign versus malignant diseases and in special populations such as
in cirrhotic patients for liver diseases. This benchmarking concept
may now be developed for other major procedures in general surgery
and in other fields.
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DISCUSSANTS
W.C. Chapman (St. Louis, MO):
I have 2 disclosures. I am one of several founders of an image
guidance technology, Pathfinder Therapeutics, and I am on an
advisory board for Novartis Pharmaceuticals.
I very much appreciate the privilege of discussing this import-
ant article on benchmarking for complications after LD hepatectomy
in over 5000 patients from 12 high-volume centers. As we have
heard, the authors assessed endpoints out to 6 months postoperatively
assessing morbidity defined by the Clavien-Dindo classification, as
well as new comprehensive classification index, or CCI, and liver
failure according to several different definitions.
Strikingly, the authors found an impressively low rate of
complications at 12% overall with centers having performed more
than 100 hepatectomies, having significantly lower rates of overall
complications, and major complications, as well as a significant
reduction in the overall CCI. The authors conclude that this outcome
analysis of healthy LDs may serve as a reference for performance in
patients undergoing major liver resection, including across different
patient populations and centers.
I have several questions for the authors.
First, how were the thresholds for individual complications
defined, and who gathered the complications in individual centers? It
is noted there was significant variability in complications reported
by center.
There has been a significant expansion of the National Sur-
gical Quality Improvement Project, or NSQIP, in the United States
and elsewhere, and this involves the use of independent reviewers of
patient outcomes for selection of complications at a predefined
threshold. Is it possible that different review systems in this analysis
accounted for the variability and definition of complications?
Second, the authors suggest that benchmarking will allow for
comparisons to hepatectomy in other settings. As noted by the
authors, this is a very different patient group compared with the
typical patient undergoing hemihepatectomy for malignancy, for
example, where the patient age, liver quality, BMI, and other
parameters would be expected to be quite different.
Why pick the 75th percentile as a benchmark–and you
touched on this, and maybe you can touch on this just a little
further–instead of the mean or median? Would this mean that
75% of programs are below the standard? And would this apply
to payment or penalty purposes?
I wonder about the proposal to use this cohort as a benchmark
for hepatectomy in the setting of intrinsic disease. In very few
settings do we ever operate on healthy individuals who otherwise
have no indication for intervention.
Next, how do these results compare with prior studies on
benchmarking in pancreaticoduodenectomy, for example? There
have been several previous reports on benchmarking in
comprehensive assessment. Perhaps you could comment on the
comparisons of CCI to other benchmarking methods.
Finally, in relation to the results seen here today, there is a
significant difference in what is described as a high-volume versus
what I would say is the super-high-volume centers with the cut point
of greater than 100 LD hepatectomies. Why has LD transplantation
taken off at such a substantially greater level such that some centers
in eastern countries, for example, have such high volume compared
with the west? Is it simply a matter of availability, or lack thereof, of
cadaveric organs, or are there other factors involved?
My congratulations to the authors on their excellent manu-
script and to Professor Clavien for his induction into the American
Surgical Association as a honorary member.
Response From P.-A. Clavien (Zurich, Switzerland):
Dr. Chapman, thank you very much for your insight into our
work and your excellent questions. I will try to answer your questions
in order.
The first question deals with which thresholds we used to define
individual complications as well as the accuracy of data collection and
independence of the data collectors at each of the 12 participating
centers. Those are indeed important issues to secure complete and
correct data collection. The threshold defining a complication is based
on the principle of our classification of complications, that is, any
deviation from the expected postoperative course is at least a grade I
complication. Among the criteria to select the ‘‘so-called’’ centers of
excellence was the availability of a prospectively collected database,
although collection was not performed by independent personal at all
centers. To minimize bias, the Zurich group–which performed the
benchmark analysis–requested re-analysis of each patient, who devel-
oped complications. Another factor minimizing underreporting is the
use of a grading system ranking complications by severity based on the
treatment used to correct the negative events. Such information is
readily available in most databases. I will comment below on the
calculation of benchmark values.
Regarding the reference to NSQIP, there is no question that
this comprehensive administrative data collection, supported by the
American College of Surgeons, is a great step in outcome research
with more than 500 hospitals using it in the United States and
elsewhere. NSQIP, however, is complex, costly, and requires extra
personal. It does not allow to assess the complication by severity or to
calculate a global index for complications. Complications are
recorded by diagnosis with a limited follow-up of 30 days. In the
current study, we found that about 20% of complications occurred
between discharge and 3 months after surgery. Considering that
NSQIP provides different information, including the CCI might be of
great value.
Your second question deals with risk adjustment. The purpose
of this study was benchmarking for the best outcome for a procedure.
This is why we chose the lower-risk population of living liver donors.
It is a first step that must be followed by benchmarking of surgery in
other populations such as those with malignant tumors or cirrhosis.
The goal is to enable individual centers to compare their results
with the best benchmarking values of the procedure, as well as risk-
adjusted benchmark values.
Your question about the 75th percentile as a benchmark
requires some clarifications. For the calculation of the benchmark
thresholds for complications by severity and the CCI, we used the
75th percentile of the median results across centers. This means that
75% of centers had a median performance that is at or better than the
benchmark, and 25%, that is, those above the benchmark perform
worse than the benchmark. We chose this approach to exclude the
outliers, and all centers, regardless of the size, contributed equally to
the benchmark values. This method gives a somewhat better picture
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of the real world and may buffer the possible underreporting of low-
grade complications.
Your next question is about comparison between CCI and other
benchmarking methods. I must admit that I have not read every article
on benchmarking. Clearly, other studies have selected other endpoints,
and usually only 1 marker such as 1- or 5-year survival, and bench-
marks are mostly used for comparison of individual centers with others
in the same area. I may just comment on a study we did about 10 years
ago with the team of John Cameron from Johns Hopkins. At that time,
we wanted to test our new classification system in their database
covering 600 cases of duodenopancreatectomy performed during a
2-year period. This study presented at the ESA, enabled to weigh each
type of complications by severity and have an understanding of the
respective postoperative events. This was a sort of benchmarking of a
single center, but we did not have the CCI at that time.
Your next question is about volume and outcome. This was not
the aim of this study, but the observation that expert centers perform-
ing more versus less than hundreds cases had significantly better
outcome in terms of CCI and major complications may highlight
some continuity in quality with volume, well over with what is
currently reported. Your last point, which is not really related to the
current benchmark analyses, is why LD is more popular in Asia than
it is in other parts of the world? I can only speculate on that: the main
reason is the lack of available cadaveric organs mostly due to cultural
and religious beliefs and high mortality on the waiting list.
J. Emond (New York, NY):
This work was beautifully presented, as always, and very
ambitious. I would express my ambivalence about the ability to apply
a benchmark to a population with such center variability in terms of
complication rates. On the table with the individual centers, those
bars were quite disparate.
I think the benchmark may well have to be established with the
big center. Comparing a center with 3000 donors, it is really hard for
me to be comfortable with the choice of an equivalent of 100 as the
benchmark, or I should say the transition point. So I would like to
challenge you to think about that a little further and whether another
way to handle this ought to be considered.
The other thing, I was reassured to see that the left lobes had
fewer problems. In our own data–and unfortunately we did not share
it today–but both functional parameters are much better for LH than
right, and you showed this, although the incidence of severe com-
plications may not be so different, so that is something that your
paper will cast a lot of light on and be very useful.
The last thing I would like to ask you is how do you evaluate
the challenge of, as expertise increases, the surgeon chooses to take
on more difficult or higher-risk procedures? That does not apply here
because the donor hepatectomy is the same, but in other types of
cancer surgery it would be a really interesting issue.
Response From P.-A. Clavien (Zurich, Switzerland):
Dr. Emond, thank you for your interest in our study. Regarding
your first question, I reacted exactly like you when I received the data
with high variation among the 12 centers, and not just between low
and high volume centers. Dr. Milo Puhan, our epidemiologist–
statistician of the study, convinced me that this was expected and
that the methodology–as discussed in my reply to Dr. Chapman’s
comments–based on the median value of the 75% percentile results
among centers would provide not just generous but realistic values.
The key is to upfront define criteria (as described in the last table of
the article), then gather credible and robust data to calculate bench-
mark values. Those represent supposedly the best achievable results
for the procedure in the real world.
Your last question about why some surgeons may take more
risk while climbing the learning curve is somewhat intuitive. My
feeling is that surgeons may refine their indications and technical
skills while gaining experience with a procedure, and consequently
feel more comfortable to take more difficult cases and perform
extended surgery. This is possibly where benchmarking may serve
as the ‘‘gatekeeper.’’
Thank you so much to both discussants for their insightful
questions and the privilege of the floor.
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